KRAS G12C MUTATION
Clinical trials for KRAS G12C MUTATION explained in plain language.
Never miss a new study
Get alerted when new KRAS G12C MUTATION trials appear
Sign up with your email to follow new studies for KRAS G12C MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat colorectal cancer mutation
Disease control ENROLLING_BY_INVITATIONThis study tests two drug combinations for people with advanced colorectal cancer that has a specific genetic change called KRAS G12C. In one group, patients who haven't had treatment yet will receive the drugs IBI351 and cetuximab β plus chemotherapy (FOLFIRI). In another group,…
Matched conditions: KRAS G12C MUTATION
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Gene-Guided drugs aim to shrink brain tumors
Disease control OngoingThis phase 2 trial tests whether genetic testing can help doctors pick the right targeted drug for people whose solid tumors have spread to the brain. About 50 participants with specific gene mutations (like NTRK, ROS1, CDK, PI3K, or KRAS G12C) will receive one of four drugs: abe…
Matched conditions: KRAS G12C MUTATION
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Scientists dig into the DNA of drug-resistant lung cancers to find hidden clues
Knowledge-focused ENROLLING_BY_INVITATIONThis study enrolls 40 people with non-small cell lung cancer whose tumors have stopped responding to targeted therapy (tyrosine kinase inhibitors). Researchers will analyze the tumors' full genetic code and RNA to find new resistance mechanisms. The goal is to better understand w…
Matched conditions: KRAS G12C MUTATION
Sponsor: Chang Gung Memorial Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC